What Patients Should Ask Before Starting Any GLP-1 or Peptide-Based Weight-Loss Plan Before starting a GLP-1 medication, peptide therapy, or any online product marketed for weight loss, patients should ask: Is this medication FDA-approved or investigational
The work of dedicated researchers is what will ultimately translate that potential into definitive answers
Combining it with other serotonergic medications such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and certain migraine medications can increase the risk of serotonin syndrome, a potentially life-threatening condition characterized by symptoms like agitation, hallucinations, rapid heart rate, fever, excessive sweating, shivering, and diarrhoea
In the CY 2025 PFS final rule (89 FR 98228 through 98275), we codified regulations implementing section 11101 of the IRA in newly added 42 CFR part 427, chapter IV, including new provisions at 427.200 and 427.201 to codify the policies regarding the computation of the inflation-adjusted beneficiary coinsurance, defined in 427.200, for Part B rebatable drugs as required by section 1847A(i)(5) of the Act
Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimers disease (AD) and Parkinsons disease (PD)
